Brief: Nurexone Biologic Receives FDA Orphan-Drug Designation
30/10/2023 13:20
Oct 30 (Reuters) - Nurexone Biologic Inc NRX.V :
* NUREXONE BIOLOGIC RECEIVES FDA ORPHAN-DRUG DESIGNATION,
ACCELERATING DEVELOPMENT OF EXOPTEN THERAPY FOR ACUTE SPINAL
CORD INJURY TREATMENT
Source text for Eikon: ID:nGNX4gjZ7H
Further company coverage: NRX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement